Sarah Elizabeth Fenton

Sarah Elizabeth Fenton

Auto-generated profile, based on publicly available information

Sarah Elizabeth Fenton

Medical Oncology, Northwestern University, Chicago, IL, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in OncoImmunology
Verified
Journal Article
Closed access
DWDaniel Y Wang
Daniel Y Wang
MMMeghan J Mooradian
Meghan J Mooradian
DKDaeWon Kim
DaeWon Kim
NSNeil J Shah
Neil J Shah
SFSarah E Fenton
Sarah E Fenton
DJDouglas B Johnson
Douglas B Johnson
Colitis is a frequent, clinically-significant immune-related adverse event caused by anti-programmed death-1 (PD-1). The clinical features, timing, and management of colitis with anti-PD-1-based regimens are not well-characterized. Patients with advanced melanoma that received either anti-PD-1 monotherapy (“monotherapy”) or combined with ipilimumab (“combination therapy”) were screened from 8 academic medical centers, to identify those with clinically-relevant colitis (colitis requiring systemic steroids). Of 1261 patients who received anti-PD-1-based therapy, 109 experienced colitis. The incidence was 3.2% (30/937) and 24.4% (79/324) in the monotherapy and combination therapy cohorts, respectively. Patients with colitis from combination therapy had significantly earlier symptom onset (7.2 weeks vs 25.4 weeks, p < 0.0001), received higher steroid doses (median prednisone equivalent 1.5 mg/kg vs 1.0 mg/kg, p = 0.0015) and experienced longer steroid tapers (median 6.0 vs 4.0 weeks, p = 0.0065) compared to monotherapy. Infliximab use and steroid-dose escalation occurred more frequently in the combination therapy cohort compared to monotherapy. Nearly all patients had resolution of their symptoms although one patient died from complications. Anti-PD-1 associated colitis has a variable clinical presentation, and is more frequent and severe when associated with combination therapy. This variability in checkpoint-inhibitor associated colitis suggests that further optimization of treatment algorithms is needed.

1 March 2010 in The American Journal of Pathology
Verified
Journal Article
Closed access
VYVipin Yadav
Vipin Yadav
NYNicole C. Yanez
Nicole C. Yanez
SFSarah E. Fenton
Sarah E. Fenton
MDMitchell F. Denning
Mitchell F. Denning

27 December 2022 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
SFSarah E. Fenton
Sarah E. Fenton
MZMarkella Zannikou
Markella Zannikou
LILiliana Ilut
Liliana Ilut
MFMariafausta Fischietti
Mariafausta Fischietti
CJChunni Ji
Chunni Ji
DSDiana Saleiro
Diana Saleiro
Immune checkpoint inhibitors (ICI) have transformed the treatment of melanoma. However, the majority of patients have primary or acquired resistance to ICIs, limiting durable responses and patient survival. IFNγ signaling and the expression of IFNγ-stimulated genes correlate with either response or resistance to ICIs, in a context-dependent manner. While IFNγ-inducible immunostimulatory genes are required for response to ICIs, chronic IFNγ signaling induces the expression of immunosuppressive genes, promoting resistance to these therapies. Here, we show that high levels of Unc-51 like kinase 1 (ULK1) correlate with poor survival in patients with melanoma and overexpression of ULK1 in melanoma cells enhances IFNγ-induced expression of immunosuppressive genes, with minimal effects on the expression of immunostimulatory genes. In contrast, genetic or pharmacologic inhibition of ULK1 reduces expression of IFNγ-induced immunosuppressive genes. ULK1 binds IRF1 in the nuclear compartment of melanoma cells, controlling its binding to the programmed death-ligand 1 promoter region. In addition, pharmacologic inhibition of ULK1 in combination with anti-programmed cell death protein 1 therapy further reduces melanoma tumor growth in vivo. Our data suggest that targeting ULK1 represses IFNγ-dependent immunosuppression. These findings support the combination of ULK1 drug-targeted inhibition with ICIs for the treatment of patients with melanoma to improve response rates and patient outcomes. Implications: This study identifies ULK1, activated downstream of IFNγ signaling, as a druggable target to overcome resistance mechanisms to ICI therapy in metastatic melanoma.

29 June 2014 in Molecular Carcinogenesis
Verified
Journal Article
Closed access
PDF file
SFSarah E. Fenton
Sarah E. Fenton
KHKelli A. Hutchens
Kelli A. Hutchens
MDMitchell F. Denning
Mitchell F. Denning

1 November 2020 in Kidney International Reports
Verified
Journal Article
Open access
ITIbrahim Tawhari
Ibrahim Tawhari
SFSarah E. Fenton
Sarah E. Fenton
JSJeffery A. Sosman
Jeffery A. Sosman
NSNedjema Sustento-Reodica
Nedjema Sustento-Reodica
YSyashpal singh
yashpal singh
VAVikram Aggarwal
Vikram Aggarwal

11 November 2014 in Experimental Dermatology
Verified
Journal Article
Closed access
PDF file
SFSarah E. Fenton
Sarah E. Fenton
MDMitchell F. Denning
Mitchell F. Denning